- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00408135
Japanese Study Evaluating Safety, Efficacy and Acceptability of Telithromycin in Children With Infections
Evaluation of the Safety, Efficacy and Acceptability of HMR 3647 (20% Fine Granules 1 g Sachet) in Children With Infections
The primary objective is to assess the safety of telithromycin (HMR 3647) (20% fine granules) 1g filling sachet in children with infections (Respiratory tract infections, Dermatological infections, Otorhinolaryngological infections, Dentistry/Oral surgery infections).
Secondary objectives are to assess the clinical efficacy, bacteriological efficacy and acceptability of telithromycin (20% fine granules) 1g filling sachet in children with infections.
Study Overview
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Tokyo, Japan
- Sanofi-Aventis
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Outpatients of weight from 7.0 kg.
- For respiratory tract infections:subjects diagnosed with mild or moderate respiratory tract infection (excluding pneumonia) based on a fever (≥ 38°C) or C-Reactive Protein positive, clinical symptoms/signs, and laboratory findings.
- For dermatological infections: subjects diagnosed with mild or moderate dermatological infection in terms of clinical symptoms/signs and laboratory findings.
- For otorhinolaryngological infections:subjects with purulent / mucopurulent rhinorrhea and postrhinorrhea, subjects diagnosed with mild or moderate otorhinolaryngological infection in terms of clinical symptoms/signs and laboratory findings
- For dental / oral surgical infections: subjects who have formed obstructive abscess and diagnosed with mild or moderate dental / oral surgical infection
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: SINGLE_GROUP
- Masking: NONE
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Safety evaluation: presence/absence of subjective/objective symptoms and abnormal laboratory findings (abnormal changes of parameters in general hematological tests and blood biochemical tests).
|
Secondary Outcome Measures
Outcome Measure |
---|
Clinical efficacy:change in the symptoms and signs at end of therapy visit and at the test of cure visit
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Norifumi Yamamoto, sanofi-aventis Japan
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- EFC6371
- HMR3647B/3104
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Infections
-
International Centre for Diarrhoeal Disease Research...Centers for Disease Control and PreventionNot yet recruitingMeasles | Rubella | Cholera | Typhoid
-
MJM BontenJanssen Research & Development, LLC; Innovative Medicines InitiativeCompletedE.Coli InfectionsUnited States, United Kingdom, Canada, France, Germany, Italy, Japan, Spain
-
PfizerCompletedGroup B Streptococcus InfectionsUnited States, South Africa, United Kingdom
-
GlaxoSmithKlineActive, not recruitingInfections, MeningococcalFinland, Poland, Spain, United Kingdom, Germany, South Africa, Dominican Republic, Israel, Honduras
-
PfizerCompletedInfections, MeningococcalAustralia, Canada, Czechia, Panama, South Africa, Turkey
-
GlaxoSmithKlineCompletedInfections, MeningococcalFinland
-
PfizerCompletedInfections, MeningococcalPhilippines
-
GlaxoSmithKlineCompletedInfections, MeningococcalUnited States, Finland, Poland
-
GlaxoSmithKlineCompleted
Clinical Trials on telithromycin (HMR3647)
-
SanofiTerminated
-
SanofiCompleted
-
SanofiCompleted
-
SanofiTerminatedTonsillitis | PharyngitisUnited States, Argentina, Chile, Costa Rica, Panama
-
SanofiCompletedChronic BronchitisFrance, Spain, Belgium, Hungary, United States, Turkey, Tunisia, Morocco
-
Enanta Pharmaceuticals, IncUnknownCommunity Acquired PneumoniaUnited States